文献速递免疫规划传染病防控与疫情报告

辉瑞-BioNTech mRNA疫苗对12-18岁人群COVID-19住院的保护效果

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-10-22

该研究为2021年6-9月在美国16州19家儿科医院开展的检测阴性病例对照研究,纳入464名12-18岁住院者(179例病例和285例对照)。结果显示,在Delta变异株为主要流行株期间,完成两剂辉瑞-BioNTech疫苗对预防COVID-19住院的效果为93%(95%CI=83%-97%)。

要点

  • 两剂辉瑞-BioNTech疫苗对12-18岁人群COVID-19住院的保护效果为93%。
  • 研究期间Delta变异株为主要流行株。
  • 住院者中72%至少有一种基础疾病,包括肥胖。

核心结论

  • 两剂辉瑞-BioNTech疫苗对12-18岁人群预防COVID-19住院高度有效。
  • 研究结果强调接种疫苗对保护美国青少年免于重症COVID-19的重要性。

研究设计与样本

  • 检测阴性病例对照研究,于2021年6月1日至9月30日在美国16州19家儿科医院开展。
  • 纳入464名12-18岁住院者,其中179例病例和285例对照,中位年龄15岁。

主要发现

  • 住院者中72%至少有一种基础疾病,包括肥胖;68%参加面对面学校学习。
  • 两剂辉瑞-BioNTech疫苗对COVID-19住院的保护效果为93%(95%CI=83%-97%),研究期间B.1.617.2(Delta)为主要流行变异株。

关键数值与推荐

  • 随机安慰剂对照试验显示,该疫苗对12-15岁人群预防门诊COVID-19的有效率为100%(95%CI=75.3%-100%)。

临床怎么用

  • 建议符合条件12-18岁人群完成两剂辉瑞-BioNTech疫苗接种以预防COVID-19住院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pfizer-BioNTech COVID-19 vaccine is authorized for use in children and adolescents aged 12-15 years and is licensed by the Food and Drug Administration (FDA) for persons aged ≥16 (1). A randomized placebo-controlled trial demonstrated an efficacy of 100% (95% confidence interval [CI] = 75.3%-100%) in preventing outpatient COVID-19 in persons aged 12-15 years (2); however, data among adolescents on vaccine effectiveness (VE) against COVID-19 in real-world settings are limited, especially among hospitalized patients. In early September 2021, U.S. pediatric COVID-19 hospitalizations reached the highest level during the pandemic (3,4). In a test-negative, case-control study at 19 pediatric hospitals in 16 states during June 1-September 30, 2021, the effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization was assessed among children and adolescents aged 12-18 years. Among 464 hospitalized persons aged 12-18 years (179 case-patients and 285 controls), the median age was 15 years, 72% had at least one underlying condition, including obesity, and 68% attended in-person school. Effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization was 93% (95% CI = 83%-97%), during the period when B.1.617.2 (Delta) was the predominant variant. This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine are highly effective at preventing COVID-19 hospitalization among persons aged 12-18 years and reinforces the importance of vaccination to protect U.S. youths against severe COVID-19.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34673751. doi:10.15585/mmwr.mm7042e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。